📊 GWLL Key Takeaways
Is GWLL a Good Investment? Thesis Analysis
GWLL exhibits severe financial distress with negative stockholders' equity of -$94.8K, indicating technical insolvency. Revenue has collapsed 92.4% YoY to essentially zero, while the company burns negative operating cash flow and carries $176.1K in long-term debt with no capacity to service it. The company faces imminent liquidity crisis without immediate capital injection or debt restructuring.
Why Buy GWLL? Key Strengths
- Current ratio of 6.37x suggests short-term current asset coverage, though largely illusory given negative equity
- Cash position of $45.6K provides minimal runway for operational adjustments
- Gross profit of $62.5K indicates some residual revenue-generating capability, though inconsistent with $0 revenue reporting
GWLL Investment Risks to Consider
- Negative stockholders' equity of -$94.8K represents technical insolvency with liabilities exceeding assets by $94.8K
- Revenue collapse of 92.4% YoY to $0.00 indicates cessation of business operations or catastrophic market loss
- Negative operating cash flow of -$3.8K combined with $176.1K debt burden and inability to service debt (interest coverage -6.6x) creates acute default risk
- No insider buying activity and complete operational shutdown suggest abandonment or imminent bankruptcy
Key Metrics to Watch
- Stockholders equity trend - recovery to positive required for viability
- Revenue stabilization - any return to non-zero sales critical indicator
- Debt restructuring or refinancing announcements - survival depends on creditor accommodation
GWLL Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.37x current ratio provides a solid financial cushion.
GWLL Profitability Ratios
GWLL vs Consumer Sector
How GOLDENWELL BIOTECH, INC. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GWLL Overvalued or Undervalued?
Based on fundamental analysis, GOLDENWELL BIOTECH, INC. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GWLL Balance Sheet & Liquidity
GWLL 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GOLDENWELL BIOTECH, INC.'s revenue has grown significantly by 199% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
GWLL Growth Metrics (YoY)
GWLL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$20.8K | N/A |
| Q2 2024 | $139 | -$20.8K | N/A |
| Q1 2024 | $158 | -$20.8K | N/A |
| Q3 2023 | $382 | -$4.6K | N/A |
| Q2 2023 | $276 | -$4.6K | N/A |
| Q1 2023 | $397 | -$4.6K | N/A |
| Q3 2022 | $11.1K | -$4.6K | N/A |
| Q2 2022 | $1.1K | -$17.8K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GWLL Capital Allocation
GWLL SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GOLDENWELL BIOTECH, INC. (CIK: 0001800373)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GWLL
What is the AI rating for GWLL?
GOLDENWELL BIOTECH, INC. (GWLL) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GWLL's key strengths?
Claude: Current ratio of 6.37x suggests short-term current asset coverage, though largely illusory given negative equity. Cash position of $45.6K provides minimal runway for operational adjustments.
What are the risks of investing in GWLL?
Claude: Negative stockholders' equity of -$94.8K represents technical insolvency with liabilities exceeding assets by $94.8K. Revenue collapse of 92.4% YoY to $0.00 indicates cessation of business operations or catastrophic market loss.
What is GWLL's revenue and growth?
GOLDENWELL BIOTECH, INC. reported revenue of $0.0.
Does GWLL pay dividends?
GOLDENWELL BIOTECH, INC. does not currently pay dividends.
Where can I find GWLL SEC filings?
Official SEC filings for GOLDENWELL BIOTECH, INC. (CIK: 0001800373) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GWLL's EPS?
GOLDENWELL BIOTECH, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GWLL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GOLDENWELL BIOTECH, INC. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GWLL stock overvalued or undervalued?
Valuation metrics for GWLL: ROE of N/A (sector avg: 18%), net margin of N/A (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy GWLL stock in 2026?
Our dual AI analysis gives GOLDENWELL BIOTECH, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GWLL's free cash flow?
GOLDENWELL BIOTECH, INC.'s operating cash flow is $-3.8K, with capital expenditures of N/A.
How does GWLL compare to other Consumer stocks?
Vs Consumer sector averages: Net margin N/A (avg: 8%), ROE N/A (avg: 18%), current ratio 6.37 (avg: 1.5).